EDITAS MEDICINE INC. - COMMON STOCK

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

27 يونيو 2024 09:45:34 بحسب NetDania Notify

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

26 يونيو 2024 10:52:15 بحسب NetDania Notify

NetDania - New 12 months Low: EDITAS MEDICINE INC. - COMMON STOCK

17 يونيو 2024 10:19:53 بحسب NetDania Notify

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

14 يونيو 2024 03:01:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

14 يونيو 2024 03:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

14 مايو 2024 10:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

10 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2024 Results and Business Updates

08 مايو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

02 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

01 مايو 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

22 أبريل 2024 16:31:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

28 فبراير 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

21 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

31 يناير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

08 يناير 2024 08:15:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

13 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

11 ديسمبر 2023 12:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

03 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

02 نوفمبر 2023 09:12:24 بحسب Nasdaq GlobeNewswire